Last reviewed · How we verify
Pneumococcal conjugate vaccine GSK1024850A
This pneumococcal conjugate vaccine stimulates the immune system to produce antibodies against multiple serotypes of Streptococcus pneumoniae by conjugating polysaccharide antigens to a protein carrier.
This pneumococcal conjugate vaccine stimulates the immune system to produce antibodies against multiple serotypes of Streptococcus pneumoniae by conjugating polysaccharide antigens to a protein carrier. Used for Prevention of invasive pneumococcal disease in infants and children, Prevention of pneumococcal disease in adults.
At a glance
| Generic name | Pneumococcal conjugate vaccine GSK1024850A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Pneumococcal conjugate vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
GSK1024850A is a conjugate vaccine that links pneumococcal capsular polysaccharides from multiple serotypes to a protein carrier, enhancing T-cell dependent immune responses. This approach improves immunogenicity compared to unconjugated polysaccharide vaccines, particularly in young children and immunocompromised populations. The vaccine induces both humoral and cellular immunity to prevent invasive pneumococcal disease.
Approved indications
- Prevention of invasive pneumococcal disease in infants and children
- Prevention of pneumococcal disease in adults
Common side effects
- Injection site erythema
- Injection site swelling
- Fever
- Irritability
- Drowsiness
Key clinical trials
- Indirect Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage
- Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A (PHASE3)
- Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease (PHASE3)
- Safety & Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First Vaccination (PHASE2)
- Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age (PHASE3)
- Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age (PHASE3)
- Evaluate Safety and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine in Preterm Born Infants. (PHASE3)
- Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: